Description

Novo Nordisk AS’s 1.5 Million-User Breakthrough — Wegovy Pill Changes The Obesity Battle!

Novo Nordisk AS reported steady progress during the second quarter of 2026, reflecting ongoing strategic initiatives across its obesity and diabetes franchises, pipeline development, and operational transformation. The company now serves over 46 million patients living with obesity and diabetes, representing a nearly 70% increase in obesity treatment patients year-over-year, with nearly 5 million on obesity treatments. A key commercial highlight was the global rollout of the Wegovy Pill, which reached approximately 1.5 million users worldwide. Notably, the U.S. launch showed robust uptake with weekly prescriptions exceeding 260,000, and the pill capturing about 90% of the oral obesity medication market despite recent competition. Internationally, strong growth was observed, particularly in the U.K. and UAE, with the Wegovy Pill quickly gaining significant market share shortly after launch.